QUEST DIAGNOSTICS INC
For the period ended Dec 31, 2024. Filed Feb 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 20, 2025
DGX$259.67+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| 2024 | 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $549 | $686 |
| Accounts receivable, net of allowance for credit losses of $29 and $27 as of December 31, 2024 and 2023, respectively | 1,304 | 1,210 |
| Inventories | 188 | 190 |
| Prepaid expenses and other current assets | 351 | 286 |
| Total current assets | 2,392 | 2,372 |
| Property, plant and equipment, net | 2,113 | 1,816 |
| Operating lease right-of-use assets | 651 | 602 |
| Goodwill | 8,856 | 7,733 |
| Intangible assets, net | 1,763 | 1,166 |
| Investments in equity method investees | 123 | 135 |
| Other assets | 255 | 198 |
| Total assets | $16,153 | $14,022 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $1,394 | $1,359 |
| Current portion of long-term debt | 602 | 303 |
| Current portion of long-term operating lease liabilities | 173 | 153 |
| Total current liabilities | 2,169 | 1,815 |
| Long-term debt | 5,615 | 4,410 |
| Long-term operating lease liabilities | 535 | 503 |
| Other liabilities | 938 | 876 |
| Commitments and contingencies | ||
| Redeemable noncontrolling interest | 83 | 76 |
| Stockholders’ equity: | ||
| Quest Diagnostics stockholders’ equity: | ||
| Common stock, par value $0.01 per share; 600 shares authorized as of both December 31, 2024 and 2023; 162 shares issued as of both December 31, 2024 and 2023 | 2 | 2 |
| Additional paid-in capital | 2,361 | 2,320 |
| Retained earnings | 9,360 | 8,825 |
| Accumulated other comprehensive loss | (88) | (14) |
| Treasury stock, at cost; 51 shares as of both December 31, 2024 and 2023 | (4,857) | (4,826) |
| Total Quest Diagnostics stockholders’ equity | 6,778 | 6,307 |
| Noncontrolling interests | 35 | 35 |
| Total stockholders’ equity | 6,813 | 6,342 |
| Total liabilities and stockholders’ equity | $16,153 | $14,022 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.